Key Facts Surrounding This News Item
- NKTR had a POWR Rating of B (Buy) coming into today.
- NKTR was -2.25% below its 10-Day Moving Average coming into today.
- NKTR was 1.43% above its 20-Day Moving Average coming into today.
- NKTR was 14.88% above its 50-Day Moving Average coming into today.
- NKTR was 52.65% above its 100-Day Moving Average coming into today.
- NKTR was 122.82% above its 200-Day Moving Average coming into today.
- NKTR had returned +41.58% year-to-date leading up to today’s news, versus a +0.31% return from the benchmark S&P 500 during the same period.
More Info About Nektar Therapeutics (NKTR)
Nektar Therapeutics is a biopharmaceutical company, developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology. View our full NKTR ticker page with ratings, news, and more.
Try StockNews.com Premium Today!
Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!